TrialVaccine2023

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.

Yumi Tsuchiya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.